Form 4: Prelude Therapeutics CFO Granted Stock Options

Laurent Chardonnet, CFO of Prelude Therapeutics, was granted stock options for 150,000 shares on March 1, 2024.

Summary

• Laurent Chardonnet, the Chief Financial Officer of Prelude Therapeutics, was granted employee stock options on March 1, 2024.
• The options grant covers 150,000 shares of Prelude Therapeutics common stock.
• The exercise price of the options is $4.59 per share.
• The options vest as to 25% on March 1, 2025, and then monthly at a rate of 1/48 of the total shares until fully vested, contingent upon continued service to the company.
• The options expire on February 28, 2034.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a standard executive compensation practice. The sentiment is slightly positive as it indicates the company is incentivizing its CFO.

Positives

• The granting of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• The vesting schedule of 25% after one year followed by monthly vesting is a typical arrangement.
• Comparing the size of the grant to similar companies would require further analysis of Prelude Therapeutics' compensation strategy and market capitalization.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CFO.
• Employees may see this as a standard practice for executive compensation.

Key Dates